Quick Answer
Maze Therapeutics, Inc. reported Revenue (ASC 606) of $167.50 million for fiscal year 2024.
Maze Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $167.50M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $0.00 | -100.0% | -100.0% |
| September 30, 2024 | $2.50M | — | -98.5% |
| June 30, 2024 | $165.00M | — | — |
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: